In a report released today, Edward Tenthoff from Piper Sandler maintained a Buy rating on Arvinas Holding Company, with a price target of $16.00. The company’s shares opened today at $9.70.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Tenthoff covers the Healthcare sector, focusing on stocks such as Arvinas Holding Company, Skye Bioscience, and Alnylam Pharma. According to TipRanks, Tenthoff has an average return of -9.9% and a 36.14% success rate on recommended stocks.
Arvinas Holding Company has an analyst consensus of Moderate Buy, with a price target consensus of $20.00, a 106.19% upside from current levels. In a report released yesterday, Barclays also maintained a Buy rating on the stock with a $15.00 price target.
The company has a one-year high of $29.61 and a one-year low of $5.90. Currently, Arvinas Holding Company has an average volume of 1.99M.
Based on the recent corporate insider activity of 29 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of ARVN in relation to earlier this year. Last month, Briggs Morrison, a Director at ARVN bought 30,000.00 shares for a total of $226,800.00.
Read More on ARVN:
/Semiconductor%20by%20Gorodenkoff%20via%20Shutterstock.jpg)
/An%20image%20of%20a%20Tesla%20humanoid%20robot%20in%20front%20of%20the%20company%20logo%20Around%20the%20World%20Photos%20via%20Shutterstock.jpg)
